The 89% CR rate with zero relapses and no neurotoxicity positions NXC-201 as a potential best-in-class CAR-T for AL Amyloidosis. The registrational trial design and BLA submission timeline (mid-2027) provide a clear catalyst path. Monitor for any competitive CAR-T data in AL Amyloidosis and for financing needs given pre-revenue status.
Price Chart
Executive Summary
Immix Biopharma reported an interim update from its Phase 2 NEXICART-2 trial showing an 89% (40/45) complete response rate across all 45 relapsed/refractory AL Amyloidosis patients, with all 25 new patients achieving CR or MRD-negativity. The company projects the CR rate could reach up to 98% based on MRD-negativity in pending patients, and plans final readout and BLA submission in mid-2027. This is a highly positive clinical data update for a pre-revenue biotech with a registrational trial design.
Key Facts
- 89% (40/45) complete response rate across all 45 relapsed/refractory AL Amyloidosis patients in Phase 2 NEXICART-2 trial, assessed by independent review committee
- 100% (25/25) of new patients are either in CR or MRD-negative (21/25 CR, 4/25 MRD-negative)
- MRD-negativity in 4 pending patients could increase future CR rate up to 98% (44/45)
- No relapses observed to date for any patient who reached CR or MRD-negativity
- No neurotoxicity or enterocolitis observed to date
- NEXICART-2 final readout and BLA submission planned in mid-2027
- NXC-201 has Breakthrough Therapy Designation, RMAT, and Orphan Drug Designation from FDA
Financial Impact
No financial data reported; pre-revenue clinical-stage biotech. Amyloidosis market estimated at $6.2B in 2025, expected to reach $6.6B in 2026.
Risk Factors
- Pre-revenue company requires additional capital to fund BLA submission and potential commercial launch
- Phase 2 data may not replicate in larger registrational dataset
- Competing therapies (e.g., Johnson & Johnson's Tecvayli, Pfizer's bortezomib-based regimens) could limit market share
- Manufacturing and commercialization execution risk for CAR-T therapy
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-044761 |
| Exhibit: ex99-1.htm | 0001493152-26-044761 |
| Document: 0001493152-26-044761-index-headers.html | 0001493152-26-044761 |
| Document: 0001493152-26-044761-index.html | 0001493152-26-044761 |
| Document: 0001493152-26-044761.txt | 0001493152-26-044761 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G | $8.00 | awaiting T+5 | — | $8.05 (+0.63%) |
Sep 30, 2026 27d ago | 8-K | $10.23 $9.29 | ▲ +9.19% | ▲ +10.49% | $8.05 (+21.31%) |
Sep 29, 2026 28d ago | 424B5 | $10.54 $9.64 | ▲ +8.54% | ▲ +10.49% | $8.05 (+23.62%) |
Sep 29, 2026 28d ago | 8-K | $10.54 $9.64 | ▼ −8.54% | ▼ −10.49% | $8.05 (−23.62%) |
Jul 20, 2026 14w ago | 8-K | $8.80 $8.52 | ▼ −3.18% | ▼ −2.76% | $8.05 (−8.52%) |
May 21, 2026 22w ago | 8-K | $8.78 $9.22 | ▼ −5.01% | ▼ −3.35% | $8.05 (+8.31%) |
May 21, 2026 22w ago | Press Release | $8.67 $9.00 | ▲ +3.81% | ▲ +1.96% | $8.05 (−7.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers